scholarly journals Efficacy of tocilizumab for refractory Takayasu arteritis: a retrospective study and literature review

2021 ◽  
Author(s):  
Haiyan Li ◽  
Zongwen Shuai
Keyword(s):  
Adverse Effect ◽  
Retrospective Study ◽  
Literature Review ◽  
Adverse Events ◽  
Takayasu Arteritis ◽  
Common Adverse Effect ◽  
Efficacy And Safety ◽  
Significant Drop ◽  
Medical University

AbstractTo evaluate the efficacy and safety of tocilizumab (TCZ) in the treatment of refractory Takayasu arteritis (TAK). Eleven refractory TAK patients treated with TCZ at the First Affiliated Hospital of Anhui Medical University between 2017 July and 2020 December were respectively analyzed. We also respectively analyzed the studies on TCZ efficacy in patients with TAK, from PubMed/MEDLINE, Elsevier Science Direct between January 2010 and April 2021. The median age of 11 patients was 34(19–46) years. After 3 months of TCZ, a significant drop was found in median NIH (3[2–5] at baseline vs 1[0–2] after 6 months; p < 0.05), ITAS-2010 score (8.5[6–11] vs 6[1–10]; p < 0.05). One (9%) patient experienced relapse during TCZ treatment. After withdrawal of TCZ, one patient (9%) underwent relapse and nine patients (81%) were spared of GC use. In literature review, a total of 211 patients (mean age 35 years) were analyzed, including 80 (38%) Chinese and 169 females (80%). Among the 211 patients, (154 patients) 73% achieved remission after the last infusion of TCZ; TAK relapsed in 6% of patients during TCZ treatment and 5% of the TCZ patients after the withdrawal of TCZ. A total of 95 types of adverse events were observed in the literature. Infection was the most common adverse effect, occurring in 50% of patients. TCZ could serve as an efficacious and safe agent for refractory TAK.

Tocilizumab in Giant Cell Arteritis: A Multicenter Retrospective Study of 34 Patients

2016 ◽  
Vol 43 (8) ◽  
pp. 1547-1552 ◽  
Author(s):  
Alexis Régent ◽  
Serge Redeker ◽  
Alban Deroux ◽  
Pierre Kieffer ◽  
Kim Heang Ly ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Side Effects ◽  
Adverse Events ◽  
Giant Cell Arteritis ◽  
Giant Cell ◽  
Multicenter Study ◽  
Efficacy And Safety ◽  
Severe Adverse Events ◽  
Retrospective Multicenter Study

Objective.To report the efficacy and safety of tocilizumab (TCZ) for giant cell arteritis (GCA).Methods.A retrospective multicenter study that included 34 patients receiving TCZ for GCA.Results.TCZ was effective in all but 6 patients, who still had mild symptoms. Mean glucocorticoid dose was tapered. One patient died and 3 patients had to stop TCZ therapy because of severe adverse events. Twenty-three patients stopped treatment; 8 of these experienced relapses after a mean of 3.5 ± 1.3 months.Conclusion.TCZ is effective in GCA. However, side effects occur. Whether this treatment has only a suspensive effect remains to be determined.

scholarly journals Techniques of hollow maxillary dentures: a literature review

2021 ◽  
Vol 8 (8) ◽  
pp. 4111
Author(s):  
Anas Omar Haroub ◽  
Alaa Mohammad Alaidarous ◽  
Mazen Thabet Alshahrani ◽  
Naif Mayouf Alrasheedi ◽  
Abdulhakeem Nasier Almodahi ◽  
...  
Keyword(s):  
Literature Review ◽  
Adverse Events ◽  
The Other ◽  
Efficacy And Safety ◽  
Denture Base ◽  
Future Studies ◽  
Significant Challenge ◽  
Atrophic Maxilla ◽  
Adequate Sample Size ◽  
Modeling Clay

Clinically, the management of severy atrophic maxilla might represent a significant challenge for the attending dentists and surgeons to successfully perform and achieve fabricated complete maxillary dentures. Making a hollow denture base for these defects has also been previously reported as a valid approach that can be used to decrease the weight of the maxillary prosthesis. Many modalities have been proposed for these procedures with favorable outcomes, and variable events of disadvantages and adverse events. This literature review aims to collect enough evidence regarding the different reported techniques of the hollow maxillary denture, according to the different studies. Many techniques have been previously reported as using magnets, using implants, intramucosal inserts, springs, suction disks, lightweight dentures, and modified impression techniques. Many materials have been previously used with the 3D spacers of the lightweight denture techniques as dental stone, silicon putty, cellophane-wrapped asbestos, light-body coated gauze, modeling clay, salt, thermocol, caramel, and glycerine soap. Favoring one of the modalities over the other requires the inauguration of future studies with an adequate sample size to validate the efficacy and safety of these modalities. All of this information is furtherly discussed within the manuscript based on the collected evidence from the different studies in the literature.

Chemotherapy Plus Hematopoietic Growth Factor for Refractory Paroxysmal Nocturnal Hemoglobinuria: Diminishing PNH Clone and Stimulating Hematopoisis

Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 4376-4376
Author(s):  
Zonghong Shao ◽  
Xifeng Dong ◽  
Rong Fu ◽  
Wen Qu ◽  
Yong Liang ◽  
...  
Keyword(s):  
Adverse Events ◽  
Paroxysmal Nocturnal Hemoglobinuria ◽  
Conflicts Of Interest ◽  
Efficacy And Safety ◽  
Free Hemoglobin ◽  
Traditional Treatment ◽  
Hematological Diseases ◽  
Transfusion Independence ◽  
Medical University ◽  
Pnh Clone

Abstract Abstract 4376 BACKGROUND Even complement inhibitor against C5 Eculizumab has been used in the treatment of paroxysmal nocturnal hemoglobinuria (PNH) acting as a “dam” protecting PNH clone and storing higher risk of hemolysis. So we carried out a study to investigate the efficacy and safety of chemotherapy plus growth factors, a traditional treatment for malignant hematological diseases, aiming at diminishing PNH clone and stimulating hematopoisis, in patients with refractory and relapsed PNH. METHODS 10 patients were enrolled in this study. These patients were admitted into General Hospital affiliated to Tianjin Medical University(TMU) between 2006 to 2010, receiving either DAG (DNR 40mg/d, d1–2; 20mg/d, d3; Ara-C 100mg/d, d1-5; G-CSF until WBC return normal) or HAG (HHT 2–3mg/d, d1-5; Ara-C 100mg/d, d1-5; G-CSF until WBC return normal) regimen chemotherapy intravenously every 4 weeks for several cycles. The primary end points were the improvement of hemoglobin levels, decreased proportion of PNH clone and dosage of corticosteroid. Biochemical indicators of intravascular haemolysis and adverse events were also assessed. RESULTS All patients responded well. Overall improvement for anemia was achieved, transfusion independence(HB can keep more than 6g/L without transfusion) was achieved in 4 patients, hemoglobin levels reached normal gradually in 1 of them, 2 patients got prolonged transfusion interval, another 4 patients did not need transfusion all the time. Elevation of hemoglobin from (58.1±12.12) g/L to (90.20±21.55) g/L (P=0.000) was achieved for the 10 patients. The dosage of corticosteroid decreased significantly from (45.84±19.05)mg to (13.00±6.75)mg (P=0.000). The results of flow cytometry demonstrated that CD59− and CD55− erythrocytes and granulocytes in peripheral blood decreased significantly in 8 patients [(20.87±11.68)% vs (7.97±10.02)%, P=0.004 for CD59− erythrocytes; (63.76±25.36)% vs (28.44±23.50)%, P=0.002 for CD55− erythrocytes; (68.25±26.05)% vs (59.53±24.60)%, P=0.007 for CD59− granulocytes; (81.47±26.13)% vs (68.14±26.53)%, P=0.003 for CD55− granulocytes]. Indicators for haemolysis also improved. In 10 patients, apart from 1 patient with normal IBIL and TBIL all the time, IBIL decreased significantly from (36.8±29.2) U/L at baseline to (18.1±12.4) U/L (P= 0.015). Free hemoglobin level, Rous test, Ham ‘s test were carried out only in some of the patients and results of which were also encouraging. No patients died during chemotherapy; most common adverse events were infection, nausea, vomiting and fatigue. The duration of bone marrow depression ranged from 10 to 33 days. CONCLUSIONS DAG/HAG regimens Chemotherapy was an effective, safe and promising therapy for PNH. Disclosures: No relevant conflicts of interest to declare.

Efficacy and safety of rituximab in systemic sclerosis: French retrospective study and literature review

2018 ◽  
Vol 17 (6) ◽  
pp. 582-587 ◽  
Author(s):  
Mathilde Thiebaut ◽  
David Launay ◽  
Sébastien Rivière ◽  
Thibault Mahévas ◽  
Syrine Bellakhal ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Systemic Sclerosis ◽  
Literature Review ◽  
Efficacy And Safety

scholarly journals Retrospective Analysis of Efficacy and Safety of Tocilizumab Treatment in Patients with Severe Systemic-Onset Juvenile Idiopathic Arthritis Followed for 12 Months

2013 ◽  
Vol 2013 ◽  
pp. 1-8
Author(s):  
E. I. Alexeeva ◽  
A. A. Baranov ◽  
R. V. Denisova ◽  
S. I. Valieva ◽  
T. M. Bzarova ◽  
...  
Keyword(s):  
Juvenile Idiopathic Arthritis ◽  
Retrospective Study ◽  
Adverse Events ◽  
Immunosuppressive Therapy ◽  
Retrospective Analysis ◽  
Inactive Disease ◽  
Efficacy And Safety ◽  
Systemic Onset

The results of the retrospective study evaluating efficacy and safety of tocilizumab treatment in 75 patients with severe systemic-onset juvenile idiopathic arthritis refractory to standard immunosuppressive therapy are presented in the paper. Inactive disease was documented in 64% of patients after 6 months of treatment and in 73% of patients after 12 months. Adverse events manifested as mild and moderate infections as well as laboratory abnormalities: leukopenia, neutropenia, and elevated aminotransferase levels.

Analysis of risk factors for complications and adverse obstetrical outcomes in women with Takayasu arteritis: a French retrospective study and literature review

2020 ◽  
Vol 39 (9) ◽  
pp. 2707-2713 ◽  
Author(s):  
Noémie Abisror ◽  
Arsene Mekinian ◽  
Eric Hachulla ◽  
Marc Lambert ◽  
Nathalie Morel ◽  
...  
Keyword(s):  
Risk Factors ◽  
Retrospective Study ◽  
Literature Review ◽  
Takayasu Arteritis ◽  
Obstetrical Outcomes

scholarly journals Efficacy and safety of Infliximab for steroid‑resistant immune‑related adverse events: A retrospective study

2021 ◽  
Vol 14 (4) ◽  
Author(s):  
Yukio Kadokawa ◽  
Mari Takagi ◽  
Tomoe Yoshida ◽  
Akitoshi Tatsumi ◽  
Keiko Fujita ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Adverse Events ◽  
Efficacy And Safety ◽  
Steroid Resistant

scholarly journals Everolimus Versus Sirolimus for Angiomyolipoma Associated with Tuberous Sclerosis Complex: A Multi-Institutional Retrospective Study in China

2021 ◽  
Author(s):  
luo cong ◽  
Yu-shi Zhang ◽  
Ming-Xin Zhang ◽  
Min-Feng Chen ◽  
Yuan Li ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Adverse Events ◽  
Tuberous Sclerosis ◽  
Oral Mucositis ◽  
Tuberous Sclerosis Complex ◽  
National Cancer Institute ◽  
Therapeutic Efficacy ◽  
Efficacy And Safety ◽  
First Choice ◽  
Significant Difference

Abstract Purpose To evaluate the efficacy and safety of everolimus and sirolimus in patients with tuberous sclerosis complex-associated angiomyolipomas (TSC-AML). Materials and Methods We performed a multi-institutional retrospective study of TSC-AML patients treated with oral everolimus or sirolimus. Angiomyolipoma volume was estimated using orthogonal measurements by MRI or CT. Adverse events (AEs) were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events. All analyses were performed using SPSS 19.0 software. Results There were high response rates in both two groups. With the prolonged medication time, the therapeutic efficacy of two agents became more significant. Everolimus had a more significant TSC-AML volume reduction after 6 and 12 months than sirolimus. More than 1/2 of everolimus patients had ≥ 50% reduction and approximately 80% of them had ≥ 30% reduction, higher than that of the sirolimus patients. Regarding safety, there was no significant difference in the incidence of AEs between the two groups. And the most common AE was oral mucositis. Conclusions Both everolimus and sirolimus are excellent therapeutic choices for TSC-AML. However, everolimus had a better therapeutic efficacy than sirolimus, especially in reducing TSC-AML volume. Therefore, everolimus is recommended as the first choice.

scholarly journals A Prospective Observational Study on the Efficacy and Safety of Infliximab-Biosimilar (CT-P13) in Patients With Takayasu Arteritis (TAKASIM)

2021 ◽  
Vol 8 ◽  
Author(s):  
Corrado Campochiaro ◽  
Alessandro Tomelleri ◽  
Silvia Sartorelli ◽  
Camilla Sembenini ◽  
Maurizio Papa ◽  
...  
Keyword(s):  
Adverse Events ◽  
Takayasu Arteritis ◽  
Inflammatory Diseases ◽  
Retention Rate ◽  
Efficacy And Safety ◽  
Open Label ◽  
Number Of Patients ◽  
Daily Dose ◽  
Experienced Grade ◽  
Switch Group

Objectives: Infliximab (IFX) is widely used in patients with refractory Takayasu arteritis (TAK). Recently, the IFX-biosimilar CT-P13 has been introduced for the treatment of inflammatory diseases. The aim of this study was to assess the efficacy and safety of CT-P13 in patients with refractory TAK.Methods: In this prospective, open-label, single-center trial, TAK patients either already on treatment with IFX-originator (switch group) or never treated with IFX (naïve group) received CT-P13 for 52 weeks. The primary outcomes of the study were: (i) number of patients with active disease at month 6; (ii) incidence of treatment-emergent adverse events at month 12. Disease activity was assessed at month 6 and month 12 by clinical evaluation (ITAS-2020, ITAS-ESR, and ITAS-CRP scores) and imaging assessment [magnetic resonance angiography (MRA) and (18F)-FDG-PET].Results: 23 patients were recruited (21 switch, 2 naïve). At baseline, 7 patients (32%) were classified as active. At month 6, one patient voluntarily dropped out and 7 patients were still active (30%), including one patient started on a different bDMARD at month 2 due to poor disease control. Mean daily dose of prednisone equivalent was significantly lower than baseline (4.2 ± 1.9 mg vs. 4.8 ± 2.1 mg, p = 0.009). At month 12, another patient was excluded because of pregnancy desire. Five patients were classified as active (24%), including two patients started on a different bDMARD at month 2 and month 6. Mean daily dose of prednisone equivalent was significantly lower than baseline (3.3 ± 2.6, p = 0.034). No patient experienced side effects during CT-P13 infusion. Overall, one patient experienced grade 1 adverse event and 9 patients experienced grade 2 adverse events. In no case hospitalization was required. CT-P13 retention rate was 90.9% at month 6 and 90.4% at month 12.Conclusion: In this study, the use of IFX-biosimilar CT-P13 in patients with refractory TAK showed satisfying efficacy and safety profile.

Sign in / Sign up

Export Citation Format

Share Document